Advertisement
Advertisement
DBVT
DBV Technologies S.A. - ADR
10.45
USDSponsored
+0.65
+6.63%
Nov 06, 15:59 UTC -5
Closed
After-Market
10.48
+0.03
+0.30%
DBV Technologies S.A. - ADR (DBVT) Earnings
DBVT Earnings Reports
Positive Surprise Ratio
DBVT beat 11 of 20 last estimates.
55%
Next Report
Date of Next Report
Mar 24, 2027
Estimate for Q4 26 (Revenue/ EPS)
$828.20K
/-$0.09
Implied change from Q3 26 (Revenue/ EPS)
-48.24%
/-87.14%
Implied change from Q4 25 (Revenue/ EPS)
+28.40%
/-60.87%
DBV Technologies S.A. - ADR earnings per share and revenue
On Oct 28, 2026, DBVT reported earnings of -0.70 USD per share (EPS) for Q3 26, missing the estimate of -0.09 USD, resulting in a -670.08% surprise. Revenue reached 1.60 million, compared to an expected 828.20 thousand, with a 93.19% difference. The market reacted with a -3.38% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.09 USD, with revenue projected to reach 828.20 thousand USD, implying an decrease of -87.14% EPS, and decrease of -48.24% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
$0.28
Surprise
+373.86%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
FAQ
What were DBV Technologies S.A. - ADR's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, DBV Technologies S.A. - ADR reported EPS of -$0.70, missing estimates by -670.08%, and revenue of $1.60M, 93.19% above expectations.
How did the market react to DBV Technologies S.A. - ADR's Q3 2026 earnings?
The stock price moved down -3.38%, changed from $10.65 before the earnings release to $10.29 the day after.
When is DBV Technologies S.A. - ADR expected to report next?
The next earning report is scheduled for Mar 24, 2027.
What are the forecasts for DBV Technologies S.A. - ADR's next earnings report?
Based on --
analysts, DBV Technologies S.A. - ADR is expected to report EPS of -$0.09 and revenue of $828.20K for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.